Mar 6 |
Zymeworks Non-GAAP EPS of -$0.16 beats by $0.28, revenue of $16.92M misses by $0.74M
|
Mar 6 |
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
|
Mar 5 |
Zymeworks Q4 2023 Earnings Preview
|
Mar 5 |
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
|
Mar 5 |
Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
|
Feb 14 |
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
|
Feb 8 |
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
|
Feb 6 |
Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
|
Jan 31 |
Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
|
Jan 4 |
Zymeworks names Jeffrey Smith as Chief Medical Officer
|